ICS Medication Optimisations The BOOMERANG programme has been activated across your region, providing your practice with the opportunity to make significant cost-savings for the region, and to receive remuneration for your practice by reviewing eligible patients. Please note that your practice will be informed before any engagement with your patients. Practice Name: National Practice Code: Programme Activation The following pathways have been activated across your region.If you would not like to participate in any of the following pathways, please opt-out by selecting the relevant box(es) below.Medication Optimisation Pathways (tick to opt-out): 1. Esomeprazole tablets to Esomeprazole capsules 2. Tolterodine XL to Tolthen® XL 3. Sodium hyaluronate eye drops to Clinoptic 4. Hypromellose eye drops (including preservative free) to agreed formulary products 5. Tiotropium hard capsules for inhalation to Tiogiva 6. Generic Quetiapine XL to Brancico® XL 7. Pentasa® suppositories to Octasa® suppositories 8. Fentanyl / Matrifen® patches to Opiodur® patches 9. Felodipine prolonged release to Delofine® XL 10. DuoResp Spiromax® to Fobumix® Easyhaler 11. Symbicort to Fobumix Easyhaler 12. Fostair® MDI to Luforbec® MDI Clinical Pathways (tick to opt-out): IIF Flu Campaign If you have opted-out of any of these programmes, please outline the reason(s) below: PEGASUS – Patient Engagement Governance-Assured Supporting the Use of Services. A new approach to patient engagement is available which can automatically identify and engage with eligible patients, educate and consent patients for the optimisations. Contacting Patients: 1. Are you happy for patients within the activated cohorts to be contacted by the Eclipse automated patient engagement interface? (NB: this will involve SMS messaging) Yes No 2. Are you happy for patients within the activated cohorts to be contacted by a patient engagement team? (NB: this will involve telephone calls) Yes No 3. Are you happy for patients to receive a feedback questionnaire for evaluation of the programme and to allow them to express any preferences with the switches? Yes No Please note, these preferences can be changed in the future, and your surgery will be contacted prior to any patient engagements at your practice. Key Contacts * Practice Admin Lead: First Name Last Name NHS Email Address: Practice Clinical Lead: First Name Last Name NHS Email Address: Thank you for your feedback.
